logo

Moehs group will attend at DCAT Week, the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries

DCAT Week

Moehs group will attend at DCAT Week, the premier business development event for companies engaged in pharmaceutical development and manufacturing and related industries

Leave a Comment / By

It will be held from March 18 to 21, 2019 in New York  City (USA) and is organized by the Drug, Chemical & Associated Technologies Association (DCAT).

 

Moehs Group will attend this exclusive meeting, because ensures that members have a forum for high-level strategic meetings with key decision makers, timely educational programs, and important networking opportunities.

Unlike many tradeshows or conferences, this meeting offers companies the opportunity to host private meetings with customers, suppliers and potential business partners in their reserved Business Meeting Space. Although those meetings are mostly pre-scheduled, DCAT Week’s activities and events offer additional opportunities for introductions, impromptu meetings and other business connections.

 

Leave a Comment

Your email address will not be published. Required fields are marked *

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.